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BACKGROUND
In September 2015, the United Kingdom introduced the multicomponent meningococ-
cal group B vaccine (4CMenB, Bexsero) into its publicly funded national immunization 
program at a reduced two-dose priming schedule for infants, with a 12-month booster.
METHODS
Using data from enhanced national surveillance of invasive meningococcal disease in 
England, we evaluated the effect of vaccination on the incidence of meningococcal 
group B disease during the first 3 years of the program. The effect of vaccination was 
assessed by comparing the observed incidence of disease with the expected incidence 
based on the incidence during the 4-year prevaccination period in equivalent cohorts 
and with the use of disease trends in cohorts of children younger than 5 years of age 
who were not eligible to receive the vaccine. Vaccine effectiveness was estimated with 
the use of the indirect screening method.
RESULTS
4CMenB uptake in England remained consistently high; data from the first 3 months 
of 2018 showed that 92.5% of children had completed the primary immunizations by 
their first birthday and 87.9% had received all three doses by 2 years. From September 
2015 through August 2018, the incidence of meningococcal group B disease in England 
(average annual birth cohort, approximately 650,000 infants) was significantly lower in 
vaccine-eligible cohorts than the expected incidence (63 observed cases as compared 
with 253 expected cases; incidence rate ratio, 0.25; 95% confidence interval [CI], 0.19 
to 0.36), with a 75% reduction in age groups that were fully eligible for vaccination. The 
adjusted vaccine effectiveness against meningococcal group B disease was 52.7% (95% 
CI, −33.5 to 83.2) with a two-dose priming schedule for infants and 59.1% (95% CI, 
−31.1 to 87.2) with a two-dose priming schedule plus a booster at 1 year). Over the 
3-year period, there were 169 cases of meningococcal group B disease in the vaccine-
eligible cohorts, and an estimated 277 cases (95% CI, 236 to 323) were prevented.
CONCLUSIONS
The 4CMenB program was associated with continued positive effect against meningo-
coccal group B disease in children in England, and protection after three doses of the 
vaccine was sustained for at least 2 years. (Funded by Public Health England.)
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Neisseria meningitidis, a major cause of meningitis and septicemia throughout the world, is associated with considerable 
morbidity and mortality. Twelve different menin-
gococcal capsular groups are recognized, of 
which six (A, B, C, W, X, and Y) are responsible 
for most cases of invasive meningococcal dis-
ease. In Europe, meningococcal group B is re-
sponsible for most cases of childhood meningo-
coccal disease, although the incidence of this 
disease has declined over the past decade.1 
Polysaccharide–protein conjugate vaccines have 
been effective in preventing meningococcal dis-
ease caused by capsular groups A, C, W, and Y 
because of the direct protection and indirect 
(herd) protection through prevention of carriage 
acquisition among vaccinated adolescents.2 The 
development of such a vaccine against meningo-
coccal group B has been challenging because of 
the structural similarity of the meningococcal 
group B polysaccharide capsule with polysialic 
acid structures on human neuronal cells, which 
results in poor immunogenicity.3
In January 2013, a protein-based, multicom-
ponent vaccine against meningococcal group B 
(4CMenB, Bexsero, GlaxoSmithKline Biologicals) 
was licensed in Europe at a three-dose priming 
schedule for infants, followed by a booster in the 
second year of life. The vaccine includes three 
recombinant proteins (factor H–binding protein 
[FHbp] peptide 1 [variant 1], neisserial heparin-
binding antigen [NHBA] peptide 2, and neisseria 
adhesin A [NadA] peptide 8 [variant NadA-2/3]), 
along with PorA P1.4–containing outer-mem-
brane vesicles from the New Zealand outbreak 
strain. This vaccine was licensed on the basis of 
safety and immunogenicity studies only, without 
real-world evidence of protection against inva-
sive disease.
The Meningococcal Antigen Typing System 
(MATS) was developed to predict strain coverage 
by 4CMenB. It comprises genotypic characteriza-
tion of PorA in conjunction with a qualitative 
and quantitative enzyme-linked immunosorbent 
assay to quantify FHbp, NHBA, and NadA ex-
pression in combination with their recognition 
by 4CMenB-induced antibodies on individual 
meningococcal isolates. This assay can be per-
formed only on culture isolates and not on 
specimens obtained from patients with disease 
confirmed by nonculture methods such as the 
polymerase-chain-reaction (PCR) test only.4 The 
MATS estimated 73% strain coverage in England 
and Wales before the introduction of 4CMenB.5
In September 2015, the United Kingdom be-
came the first country to offer 4CMenB to all 
infants free of charge. The vaccine is offered at 
8 and 16 weeks of age, with a booster at 12 
months. At the start of the program, an oppor-
tunistic catch-up vaccination was also offered to 
children at 12 and 16 weeks of age at their rou-
tine immunization visits. Within 10 months af-
ter the program began, cases of meningococcal 
group B disease in infants who were eligible to 
receive the vaccine had nearly halved, and the 
effectiveness of two doses of vaccine was 82.9% 
(95% confidence interval [CI], 24.1 to 95.2) 
against all cases of laboratory-confirmed inva-
sive meningococcal group B disease in infants.6 
In 2016, the first infants who received the pri-
mary immunizations became eligible for the 
12-month booster. Here, we report the effect and 
effectiveness of 4CMenB with regard to invasive 
meningococcal group B disease in infants and 
children at 1 year of age and 2 years of age after 
the first 3 years of the national immunization 
program in England.
Me thods
Disease Surveillance and Vaccine Uptake
Public Health England conducts enhanced na-
tional surveillance for invasive meningococcal 
disease in England.6 Briefly, hospital laboratories 
routinely submit isolates obtained from patients 
with invasive meningococcal disease to the 
Meningococcal Reference Unit of Public Health 
England for confirmation and serogrouping. 
Since 2014, all isolates of invasive meningococ-
cal group B have undergone testing with the 
MATS.6 The Meningococcal Reference Unit also 
provides a free meningococcal PCR testing ser-
vice for patients with suspected meningococcal 
disease across England, and the Immunisation 
and Countermeasures Division at Public Health 
England provides public health and vaccination 
advice for individual patients and supports the 
investigation and management of suspected 
clusters and outbreaks. As a result of the multi-
ple data sources used for surveillance, case ascer-
tainment has remained consistently high across 
all age groups.7,8 Public Health England routinely 
collects data on the vaccination history, risk fac-
tors, clinical presentations, and outcomes of all 
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patients with invasive meningococcal disease. 
Full details of the meningococcal surveillance 
plan in England are available at www . gov . uk/ 
 government/ publications/ meningococcal - disease 
- enhanced - surveillance - plan.
Data on vaccine uptake in England are rou-
tinely collected through primary care and child 
health information systems. In addition to report-
ing the percentage of eligible children who re-
ceived two doses by 12 months and three doses 
by 18 months, the timing of vaccination in days 
of age was calculated with the use of individual-
level data from local child health information 
systems (see the Supplementary Appendix, avail-
able with the full text of this article at NEJM.org).
Study Design and Support
The authors had sole responsibility for the study 
design; the data collection, analysis, and inter-
pretation; and the writing of the manuscript. All 
the authors are employed by Public Health 
England, the study funder, which is a public 
body and an executive agency of the U.K. Depart-
ment of Health. The first author had full access 
to all the data and final responsibility for the deci-
sion to submit the manuscript for publication.
Statistical Analysis
The population effect was estimated with the 
use of national surveillance data on cases of 
laboratory-confirmed meningococcal group B dis-
ease. We calculated the change in the incidence 
of the disease from 4 prevaccine surveillance 
years (September through the following August) 
to the first 3 complete years after 4CMenB was 
introduced. The age groups for the analysis were 
the following: 0 to 8 weeks (infants who were 
too young for vaccination), 9 to 17 weeks (part 
of this group was eligible for one 4CMenB dose 
in the 2015–2016 surveillance year, and the 
whole group was eligible for one 4CMenB dose 
in 2016–2017 and 2017–2018), 18 to 51 weeks 
(part of this group was eligible to receive two 
4CMenB doses in 2015–2016, and the whole 
group was eligible in 2016–2017 and 2017–2018), 
1 year (part of this group was eligible to receive 
three doses in 2016–2017, and the whole group 
was eligible to receive three doses in 2017–2018), 
2 years (part of this group was eligible to receive 
three doses in 2017–2018), and 3 to 4 years (chil-
dren who were too old to receive 4CMenB 
throughout the study period).
To estimate effect in each vaccine-eligible 
group, we initially estimated incidence rate ratios 
by comparing the numbers of cases of disease in 
each postvaccination surveillance year with those 
in the equivalent cohort during the 4 prevaccina-
tion years. To account for any changes over time 
that were unrelated to meningococcal group B 
vaccination, the incidence rate ratios were then 
adjusted for changes in the incidence of menin-
gococcal group B disease in all children younger 
than 5 years of age who were not in the vaccine-
eligible cohorts. This was possible because the 
meningococcal group B immunization program 
for infants does not provide any indirect protec-
tion to unvaccinated children. Full details regard-
ing the Poisson models used for estimation of 
the incidence rate ratios and the predicted inci-
dence in the absence of vaccination are provided 
in the Supplementary Appendix. Estimates of in-
cidence rate ratios and 95% confidence intervals 
have not been adjusted for multiple comparisons, 
so inferences based on these intervals may not 
all be reproducible.
Vaccine effectiveness was estimated in chil-
dren who were eligible to receive the vaccine 
through the routine program (i.e., those born on 
or after July 1, 2015) and who had laboratory-
confirmed invasive meningococcal group B dis-
ease with an onset between September 1, 2015, 
and August 31, 2018. Children who were eligible 
for opportunistic vaccination (i.e., those who 
were born in May or June 2015) were excluded 
because their priming schedules were different 
and their vaccine uptake was not as well docu-
mented. Children were included if they were at 
least 77 days of age and younger than 13 months 
at the onset of disease (for estimates of the ef-
fectiveness of one dose), at least 133 days of age 
and younger than 13 months (for estimates of 
the effectiveness of two doses), and at least 365 
days of age (for estimates of the effectiveness of 
three doses). Vaccine doses received by children 
with confirmed disease were counted if the on-
set occurred at least 14 days after the dose was 
received. The comparator group included all 
children who were eligible to receive 4CMenB in 
England.
If 4CMenB was protecting infants from me-
ningococcal group B disease, then the percent-
age of vaccinated children with confirmed dis-
ease would be lower than the percentage of 
children who were vaccinated in the whole popu-
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lation. The formula for vaccine effectiveness 
(VE) based on this screening method9 is
VE = 1 − [PCV/(1 − PCV)]/[PPV/(1 − PPV)],
where PCV is the percentage of vaccinated chil-
dren with meningococcal group B disease and 
PPV is the vaccine coverage in infants across 
England who were born in the same year and 
month and at an age in days exactly 14 days 
younger than the age of the child at disease on-
set (the comparator cohort for each individual 
child with the disease) (see the Supplementary 
Appendix). This 14-day period allows for an im-
mune response to develop after vaccination. In 
order to use this age-matched and period-matched 
coverage for each child with disease, logistic 
regression was used with the vaccination status 
of the child as the binary outcome variable, only 
a constant fitted, and an offset for the log odds 
of the matched coverage. Vaccine effectiveness 
was calculated as 1 minus the odds ratio in the 
model. Vaccine effectiveness was assessed this 
way according to the number of doses: one pri-
mary dose with meningococcal group B disease 
diagnosed before 13 months of age; two pri-
mary doses with meningococcal group B disease 
diagnosed before 13 months of age; and the 
complete three-dose schedule with meningococ-
cal group B disease diagnosed before 36 months 
of age. To estimate vaccine effectiveness accord-
ing to the number of doses, the coverage for the 
equivalent number of doses in the population 
was used. Data were analyzed with the use of 
Stata software, version 14 (StataCorp).
Since 4CMenB does not protect against all 
meningococcal group B strains, the results of 
the MATS testing of isolates of invasive menin-
gococcal group B obtained from vaccinated 
children were used to estimate the vaccine strain 
coverage of meningococci causing invasive dis-
ease in the different vaccinated cohorts. To esti-
mate vaccine effectiveness against vaccine-pre-
ventable meningococcal group B strains only, 
the vaccine effectiveness against all meningococ-
cal group B disease (vaccine effectivenessall) was 
adjusted by applying the proportion (p) of cul-
ture-confirmed cases in vaccinated children that 
were MATS-positive to the total number of con-
firmed cases of meningococcal group B disease 
with MATS results in that cohort. The adjusted 
vaccine effectiveness (VEmats) assumed no protec-
tion against MATS-negative strains. The follow-
ing formula was used:
VEmats = 1 – 1/{1+ [1/p] × [VEall/(1 – VEall)]}.
The derivation is provided in the Supplemen-
tary Appendix.
R esult s
Vaccine Uptake
In England, 4CMenB uptake has remained con-
sistently high since the vaccine was introduced 
into the national program in September 2015 
(Fig. 1A). Data from the first 3 months of 2018 
showed that 92.5% of children in England (aver-
age annual birth cohort, approximately 650,000 
infants) had completed the primary immuniza-
tions by their first birthday and 87.9% had re-
ceived all three doses by 2 years. In a representa-
tive sample of approximately 60,000 infants 
receiving the first dose, approximately 60,000 
receiving the second dose, and approximately 
30,000 receiving the booster in different geo-
graphic areas across England (see the Supple-
mentary Appendix), the median age at 4CMenB 
vaccination was 61 days (interquartile range, 58 
to 67) for the first dose, 128 days (interquartile 
range, 120 to 144) for the second dose, and 387 
days (interquartile range, 377 to 407) for the 
booster (Fig. 1B).
Effect of Vaccination
The fitted model showed a 29% increase in the 
number of cases between 2013–2014 and 2017–
2018, based on the observed number of cases of 
meningococcal group B disease in unvaccinated 
cohorts (P = 0.11) (Fig. 2). The model for estimat-
ing effect showed no evidence of lack of fit 
(P = 0.57), indicating that it was reasonable to 
assume that changes in cohorts of children who 
were not eligible to receive the vaccine because 
of age would have also occurred in the vaccine-
eligible cohorts.
The estimates of adjusted incidence rate ra-
tios show significant decreases in the incidence 
of meningococcal group B disease in all vaccine-
eligible cohorts of children who received at least 
two doses of 4CMenB, including those in which 
only some of the group were eligible for vaccina-
tion (Table 1). In children who were 18 to 51 
weeks of age, there were fewer cases of meningo-
The New England Journal of Medicine 
Downloaded from nejm.org at ST GEORGES University on January 24, 2020. For personal use only. No other uses without permission. 
 Copyright © 2020 Massachusetts Medical Society. All rights reserved. 
n engl j med 382;4 nejm.org January 23, 2020 313
Meningococcal Group B Vaccination of Infants
coccal group B disease than expected for 3 con-
secutive years. In the second year of the pro-
gram, fewer than expected cases were also 
observed in children who were 1 year of age and 
who became eligible for a three-dose schedule 
after July 2016. This cohort continued to benefit 
from vaccination in the third year of the pro-
gram, with significantly fewer cases observed 
among children who were 2 years of age during 
2017–2018 (Fig. 2).
When the age groups in which all children 
were eligible for vaccination were combined, the 
reduction in the incidence of meningococcal 
group B disease was 75% (63 observed cases as 
compared with 253 expected cases; incidence 
rate ratio, 0.25; 95% CI, 0.19 to 0.36), as com-
pared with a reduction of 45% in the cohorts in 
which only some children were eligible (106 
observed cases as compared with 193 expected 
cases; incidence rate ratio, 0.55; 95% CI, 0.43 to 
0.70). The difference between the number of 
observed cases (169 cases) and expected cases 
(446 cases) of meningococcal group B disease in 
the vaccine-eligible cohorts was 277 (95% CI, 
236 to 323) in the first 3 years of the program 
(i.e., 62% fewer cases than expected).
Vaccine Effectiveness
Of the 187 children with meningococcal group B 
disease who were born after July 1, 2015, a total 
of 147 who were at least 77 days of age were 
eligible for the vaccine effectiveness analysis. 
The adjusted vaccine effectiveness for a single 
dose of 4CMenB was 24.1% (95% CI, −37.6 to 
58.2) according to data on 74 children with dis-
ease (16 children who had not received the vac-
cine and 58 who had received one dose). Of the 
children with an onset of meningococcal group 
B disease between 133 days and 13 months of 
age, 4 were unvaccinated and 37 had received 
two doses of 4CMenB. Thus, the adjusted vac-
cine effectiveness was 52.7% (95% CI, −33.5 to 
83.2). In this group, 26 children had disease that 
was confirmed by culture and, of these, 16 (62%) 
had MATS-positive disease. Assuming that only 
the MATS-positive strains were preventable by 
4CMenB, the estimated vaccine effectiveness 
against vaccine-preventable meningococcal group 
B strains among children who received two 
doses was 64.4%.
Meningococcal group B disease developed in 
29 infants who were eligible for the three-dose 
schedule, including 25 who had received the three 
recommended doses. The adjusted vaccine effec-
tiveness among children who received three doses 
was 59.1% (95% CI, −31.1 to 87.2). Of the 12 iso-
lates obtained from children with culture-con-
firmed disease, 7 (58%) were MATS-positive. The 
estimated vaccine effectiveness against vaccine-
Figure 1. 4CMenB Vaccine Coverage, According to Recipients’ Month  
and Year of Birth and Age at Vaccination.
Panel A shows vaccine coverage by 12 months for the first and second doses 
of the meningococcal group B vaccine (4CMenB), as well as uptake of the 
12-month booster by 18 months of age. Panel B shows vaccination cover-
age according to age in days at the time of the first dose of the vaccine, the 
second dose, and the booster dose among infants born in the months with 
the lowest (July 2015, lower dashed line), median (January 2017, solid line), 
and highest (March 2016, upper dashed line) final vaccine coverage. The first 
dose was offered at 8 weeks of age, the second dose was offered at 16 weeks 
of age, and the booster dose was offered at 12 months.
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preventable meningococcal group B strains among 
children who received three doses was 71.2%.
Discussion
This study provides real-world evidence of the 
effectiveness of 4CMenB in preventing invasive 
meningococcal group B disease 3 years after its 
introduction into the U.K. national infant im-
munization program. Our analysis included all 
children with meningococcal group B disease in 
the vaccine-eligible cohorts, irrespective of vac-
cination status or strain coverage. We found that 
the 12-month booster protected against menin-
gococcal group B disease for at least 2 years, 
which is reassuring given the initial concerns 
about rapidly waning levels of antibodies.10 This 
is particularly important because the highest 
burden of meningococcal group B disease in 
England occurs during the first 3 years of life.11 
Our point estimates of vaccine effectiveness are 
consistent with the reduction in cases of menin-
gococcal group B disease in each of the vaccine-
eligible cohorts; the estimates of vaccine effec-
tiveness have wide confidence intervals because 
of the small numbers of cases. T
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e.Figure 2 (facing page). Number of Children with Meningo-
coccal Group B Disease in Each Surveillance Year.
The orange diamonds indicate children who were fully 
eligible to receive the vaccine, the green diamonds those 
who were partially eligible to receive the vaccine, and 
the blue diamonds those in the comparator cohorts. 
The fitted prediction in the absence of vaccination (blue 
line) and its 95% prediction interval (gray region) are 
also shown. Data shown for each year are from Septem-
ber through August. Infants who were 8 weeks of age 
or younger (Panel A) were not eligible to receive the 
vaccine. Among infants who were 9 to 17 weeks of age 
(Panel B), some infants in 2015–2016 (green diamond) 
and all the infants in the 2016–2017 and 2017–2018 
 periods (orange diamonds) were eligible to receive one 
dose. Among infants who were 18 to 51 weeks of age 
(Panel C), some infants in 2015–2016 (green diamond) 
and all the infants in the 2016–2017 and 2017–2018 peri-
ods (orange diamonds) were eligible to receive two doses. 
Among children who were 1 year of age (Panel D), some 
children in 2016–2017 (green diamond) and all the chil-
dren in 2017–2018 (orange diamond) were eligible to 
receive two priming doses plus a 12-month booster. 
Among children who were 2 years of age (Panel E), some 
children in 2017–2018 (green diamond) were eligible  
to receive two priming doses plus a 12-month booster. 
Children who were 3 and 4 years of age (Panels F and G) 
were not eligible to receive the vaccine.
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The strength of this study lies in the consis-
tently high vaccine uptake nationally and the near 
real-time enhanced national surveillance for all 
laboratory-confirmed cases, which is facilitated 
by the provision of a single national meningo-
coccal reference unit. This surveillance allows 
for rapid assessment of vaccine effect and effec-
tiveness at a national level. Our previous model, 
which used common trend lines for the expected 
cases,6 did not fit the data after 2013–2014 be-
cause of an increase in cases of meningococcal 
group B disease in the cohorts of children who 
were not eligible to receive the vaccine (P = 0.002 
for testing for goodness of fit). Inclusion of the 
year as a factor improved the model (P = 0.57 for 
testing for goodness of fit); this indicates that 
it was reasonable to assume that the secular 
changes observed in the nonvaccinated cohorts 
could be used to predict what would have hap-
pened without vaccination. The use of cases of 
disease from cohorts of children who were not 
eligible to receive the vaccine in order to predict 
disease trends in vaccine-eligible age groups can 
be justified because the program for infants is 
not expected to have any indirect (herd) effect.
The estimate of vaccine effectiveness is based 
on protection against all meningococcal group B 
strains. This is likely to be an underestimate of 
the true vaccine effectiveness because 4CMenB 
should not protect against all meningococcal 
group B strains. We attempted to estimate vac-
cine effectiveness against vaccine-preventable me-
ningococcal group B strains by adjusting for the 
proportion of MATS-positive strains among the 
smaller number of culture-confirmed cases in 
the vaccine-eligible cohort. Our estimates also 
assumed that the proportion of strains that were 
MATS-positive would be similar in culture-con-
firmed and PCR-confirmed cases. In addition, we 
assumed no protection against MATS-negative 
strains, although there is likely to be some cross-
protection, particularly in toddlers who will have 
received all three doses in the complete 4CMenB 
immunization schedule in the United Kingdom.12 
Finally, if 4CMenB protects only against these 
vaccine-preventable, MATS-positive meningococ-
cal group B strains (although meningococcal 
group B disease would be less likely to develop 
in fully-immunized infants overall), then the 
smaller number of cases that do occur in immu-
nized children would be more likely to be unpre-
ventable by the vaccine (i.e., MATS-negative), al-
though some cases of genuine vaccine failure will 
also occur. More accurate vaccine effectiveness 
against the vaccine-preventable strains may be 
possible with larger numbers of cases over time 
and improved nonculture methods of character-
ization of meningococci causing invasive disease.
In keeping with our previous report,6 vaccine 
effectiveness among children who received a sin-
gle priming dose in infancy was only 24.1% 
against all meningococcal group B strains, which 
is consistent with the lack of effect seen in infants 
who were 9 to 17 weeks of age. Vaccine effective-
ness among infants who received two priming 
doses of 4CMenB was 52.7% — lower than pre-
viously reported.6 This may be due to small num-
bers of cases in the earlier analysis and exclu-
sion of the catch-up cohort from the current 
analysis. It could also be due to waning of pro-
tection within the first year of life, which may 
not have manifested in the previous analysis be-
cause of a shorter follow-up period.
The effectiveness of 4CMenB is also supported 
by data from a recent clinical trial,13 a recent 
systematic review,14 and other observational 
studies.15-20 Although 4CMenB was licensed with 
a schedule of three priming doses in infants plus 
one booster dose, on the basis of limited data on 
immunogenicity, the United Kingdom imple-
mented a reduced schedule for infants of two 
doses plus one booster dose.21 This schedule has 
now been validated in a randomized, controlled 
trial that showed seroprotection in nearly all in-
fants who received two priming doses.13 In 2014, 
a mass immunization program was initiated in 
a region in Quebec, Canada, in response to a 
local outbreak of meningococcal group B dis-
ease; in that program, 82% of 59,000 persons 
who were 2 months to 20 years of age were im-
munized.15 No cases of meningococcal group B 
disease occurred among vaccinees, and a multi-
variate analysis showed an estimated 78% reduc-
tion in meningococcal disease after the cam-
paign. 4CMenB has also been administered to 
several thousand students during outbreaks in 
universities, and no additional cases have been 
identified.16,18-20,22 As of December 2019, no ma-
jor safety concerns had been identified after 
more than 3 million doses had been adminis-
tered to infants,23 older children and adoles-
cents,24,25 and premature infants.26 Unlike the 
polysaccharide–protein conjugate vaccines, how-
ever, 4CMenB does not have any effect on menin-
The New England Journal of Medicine 
Downloaded from nejm.org at ST GEORGES University on January 24, 2020. For personal use only. No other uses without permission. 
 Copyright © 2020 Massachusetts Medical Society. All rights reserved. 
n engl j med 382;4 nejm.org January 23, 2020 317
Meningococcal Group B Vaccination of Infants
gococcal group B carriage in immunized adoles-
cents; therefore, immunization strategies with 
4CMenB will need to focus on direct (individ-
ual) protection against meningococcal group B 
disease.27
In conclusion, 3 years after its implementation, 
4CMenB continued to protect infants and tod-
dlers against invasive meningococcal group B 
disease. This protection lasted for at least 2 years 
after receipt of two doses plus a booster dose.
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